课题基金 / 基金详情

项目摘要

项目成果

DAVID HUBACHER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Unintended pregnancy remains a stubborn problem in the United States, particularly among younger women. Better access to long-acting reversible contraception (LARC) may help this population avoid unintended pregnancy and the dilemmas of considering abortion. The questions are whether LARC can be sufficiently desirable to use, and provide better protection from unintended pregnancy relative to the alternatives. Currently, many barriers prevent uptake of LARC, and thus a true measure of its potential is unknown. If LARC is found to be superior to other methods, more effort can be made to rejuvenate existing health programs and ensure that LARC is a guaranteed option for all those who want it. In the proposed study, women aged 18-29 seeking oral or injectable contraception will be offered an opportunity to try LARC instead; the FDA-approved options include two types of intrauterine products and one type of subdermal contraceptive implant. Over a 12 month period, the experiences of LARC users will be compared to the experiences of those opting for their initial short-acting method. It is expected that 38% of participants using short-acting methods will stop using them during the first year and be at risk of unintended pregnancy; in contrast, less than 20% of LARC users will want to have their contraceptive removed. Continuation rates will be measured and pregnancies will be tallied in the two groups to document any differences that emerge. To assemble the proper evidence for fair comparisons, innovative strategies are needed. First, a hybrid intervention trial will be used to recruit two types of participants: those who have strong preferences for a particular method and those who would be willing to use a randomly assigned option. The randomized component and analysis will be used to isolate the contribution LARC can have in preventing unintended pregnancy. The cohort formed by choice of method will be used to document natural use patterns and provide comparative data. Participant attitudes toward LARC will identify barriers to more widespread uptake; a qualitative sub-study consisting of in-depth participant interviews will collect nuanced data on reasons for uptake and discontinuation of short and long-acting methods. The evidence gathered from this study will help determine whether the perceived benefits of LARC can help alleviate the difficult problem of unintended pregnancy in the US. If so, the results will help stimulate progress toward that goal.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.ajog.2016.08.033
发表时间: 2017-02
期刊: American journal of obstetrics and gynecology
影响因子: 9.8
作者: [Hubacher D, Spector H, Monteith C, Chen PL, Hart C]
通讯作者: Hart C
Opportunity, satisfaction, and regret: Trying long-acting reversible contraception in a unique scientific circumstance.
机会、满足和遗憾:在独特的科学环境下尝试长效可逆避孕。
DOI: 10.1080/03630242.2018.1478363
发表时间: 2019
期刊: Women & health
影响因子: 1.6
作者: [Burke,HollyM, Packer,CatherineA, Spector,HannahL, Hubacher,David]
通讯作者: Hubacher,David
Clinical trial with the levonorgestrel intrauterine system to measure changes in hemoglobin and serum ferritin among anemic women in Kenya
  • 批准号:
    10688071
  • 项目类别:
  • 资助金额:
    $49.75万
  • 财政年份:
    2020
  • 负责人:
    DAVID HUBACHER
  • 依托单位:
Clinical trial with the levonorgestrel intrauterine system to measure changes in hemoglobin and serum ferritin among anemic women in Kenya
  • 批准号:
    10221015
  • 项目类别:
  • 资助金额:
    $51.31万
  • 财政年份:
    2020
  • 负责人:
    DAVID HUBACHER
  • 依托单位:
Clinical trial with the levonorgestrel intrauterine system to measure changes in hemoglobin and serum ferritin among anemic women in Kenya
  • 批准号:
    10456074
  • 项目类别:
  • 资助金额:
    $49.93万
  • 财政年份:
    2020
  • 负责人:
    DAVID HUBACHER
  • 依托单位:
Long-acting Reversible Contraception: New Research to Reduce Unintended Pregnancy
  • 批准号:
    8027074
  • 项目类别:
  • 资助金额:
    $51.0万
  • 财政年份:
    2011
  • 负责人:
    DAVID HUBACHER
  • 依托单位:
海外基金